The effects of nonpromoting and weakly promoting diterpenes on skin tumor promotion by 12-0-tetradecanoylphorbol 13-acetate (TPA) were investigated. When phorbol and phorbol 12,13-diacetate (both nonpromoting) were given simultaneously with TPA after 7,12-dimethylbenz[aJ anthracene (DMBA) initiation in female mice, they had no effect on TPA promotion. However, the nonpromoter 4-0-methyl-TPA and the weak promoter mezerein were found to inhibit TPA promotion in a dose-dependent manner when given simultaneously with TPA. Because mezerein was found to be an effective inhibitor of TPA promotion when given simultaneously and because it induces many biological responses similar to those to TPA, the capacity of mezerein to act as an incomplete promoter in a two-stage promotion protocol was also investigated. Twice-weekly applications of 1, 2, or 5 ,ug of TPA for 2 weeks after DMBA initiation produced 0, 0, and 0.5 papilloma per mouse, respectively, at 20 weeks. When the twiceweekly applications of TPA for 2 weeks were followed by twice-weekly treatments with 2 ;sg of mezerein for 18 weeks, the number of papillomas per mouse was 2.2, 3.5, and 9.0, respectively. Twice-weekly applications of 2 ,g of TPA for 2 weeks followed by twice-weekly treatments with 1, 2, or 4 ,g of mezerein for 18 weeks produced 2.1, 3.5, and 6.8 papillomas per mouse, respectively, in DMBA-treated mice. Twice-weekly doses as high as 40 jg of 4-0-methyl-TPA were not effective in producing tumors when given after a limited treatment with TPA; however, 4-Omethyl-TPA had weak activity as a first-stage promoter. The results suggest that although mezerein by itself is a weak promoter and mimics TPA in many biochemical and morphological effects it is a potent second-stage promoter in a two-stage promotion regimen.
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Skin tumors can be induced by the sequential application of a subthreshold dose of a carcinogen (initiation phase) followed by repetitive treatment with a noncarcinogenic promoter. The initiation phase requires only a single application of either a direct or an indirect carcinogen and is essentially an irreversible step; the promotion phase is reversible initially and later becomes irreversible (1, 2) . In addition to causing epidermal inflammation and hyperplasia, the phorbol ester tumor promoters have been shown to have several other biological effects on the skin: they alter skin cell morphology (3), decrease epidermal differentiation (3) (4) (5) (6) , induce a new cell type, called "dark cells," in adult skin (3) (4) (5) (6) , induce embryonic proteins in adult skin (7), increase RNA, protein, and DNA synthesis (8) , increase phospholipid synthesis (9) , increase ornithine decarboxylase activity (10) , increase protease activity (11) , increase histone synthesis and histone phosphorylation (12, 13) , and decrease the isoproterenol stimulation of cyclic AMP (14) and histidase activity (15) . Also, the tumor-promoting potency in vivo of a series of phorbol esters correlated well with their ability to stimulate ornithine decarboxylase activity and DNA synthesis in epidermal cells in culture (16) .
Furthermore, the phorbol esters have been shown to have several effects on cells in culture. These include increased cell transformation by chemical carcinogens and radiation in cell culture (17, 18) , comitogenic activity in lymphocytes (19) , induction of plasminogen activator production in cultured cells (20) , inhibition of terminal differentiation in Friend erythroleukemia cells (21) , chicken myoblasts (22) , neuroblastoma cells (23) , chondroblasts (24) , and adipose cells (21) , stimulation of terminal differentiation in human myeloid leukemia cells and human melanoma cells (25, 26) , increased Epstein-Barr virus expression in lymphoblastoid cell lines and Epstein-Barr virus transformation of human cells (27, 28) , increased transformation of rat embryo cells by adenovirus (29) , decreased large external transformation-sensitive glycoprotein (30) , inhibition of collagen synthesis and stimulation of 2-deoxyglucose transport in chicken embryo fibroblasts (31), interaction with epidermal growth factor receptors (32) (33) (34) , and membrane changes (35) .
It is difficult to determine which of the many phorbol ester tumor promoter-related responses are essential components of the promotion process. There is a good correlation between the promoting abilities of a series of phorbol esters and their ability to stimulate epidermal hyperplasia (36) ; however, the correlation fails with non-phorbol ester hyperplastic agents (37) . O'Brien et al. (10) reported that there is an excellent correlation between the tumor-promoting ability of various compounds (phorbol esters as well as non-phorbol ester compounds) and their ability to induce ornithine decarboxylase activity in mouse skin. However, mezerein [a diterpene similar to 12-O-tetradecanoylphorbol 13-acetate (TPA)] is capable of bringing about most of the biochemical and morphological changes seen with TPA (Table 1) , especially the induction of cell proliferation and ornithine decarboxylase by mezerein, but TPA was at least 50 times more active as a promoter (39) .
The purpose of this study was to determine the effects of nonpromoting or weakly promoting compounds such as mezerein, phorbol, phorbol 12,13-diacetate, and 4-0-methyl-TPA on the promoting ability of TPA in order to obtain clues to possible receptor characteristics and to discover potent incomplete promoters. Because of the similarities in response between mezerein and TPA, we thought that mezerein would be good to use in a two-stage promotion protocol (conversion and propagation) as originally reported by Boutwell (2) The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U. S. C. §1734 solely to indicate this fact. 
RESULTS AND DISCUSSION
The effects of various diterpene compounds, given simultaneously with TPA, on TPA tumor promotion are shown in Table  2 . When phorbol or phorbol 12,13-diacetate (both nonpromoting) were given simultaneously with TPA after DMBA initiation, they had no effect on TPA promotion. However, the nonpromoter 4-0-methyl-TPA and the weak promoter mezerein were found to inhibit TPA promotion in a dose-dependent manner when given simultaneously with TPA. Although 4-O-methyl-TPA is nonpromoting, its three-dimensional structure is very c4lose to that of TPA (40) , which may allow it to compete with the putative TPA receptor. Fig. 1 shows the structures of TPA, 4-0-methyl-TPA, and mezerein. Mezerein, a plantderived ester of 12-hydroxydaphentoxin, is also a diterpene containing cyclopenterone rings and a long-chain lipophilic group at position 12. Phorbol and phorbol 12,13-diacetate both lack a long-chain lipophilic group, which may be related to their lack of inhibitory effect.
Because of the many similarities in morphological and biochemical responses induced by TPA and mezerein (Table 1) , we thought that mezerein, although a weak promoter, would be a good compound to use in the second stage of a two-stage promotion protocol as originally reported by Boutwell (2) . In his work, after DMBA initiation, the conversion stage was accomplished by a limited number of croton oil treatment which only gave a few tumors with no further treatment, and the propagation stage was accomplished by repeated treatment of turpentine which is a nonpromoting hyperplastic agent. The three-stage protocol (initiation/conversion/propagation) gave a significant tumor response but less than that when croton oil was given for the complete promotion step (2) . However, recent results suggest that nonpromoting hyperplastic agents such as turpentine, EPP, and acetic acid, when given repetitively after a few treatments with TPA, are not able to complete the promotion process as reported by Boutwell (6, 37) . In fact, Raick (6) (Table 5 ). The EPP data agree well with those reported by Raick (6) and with those for other agents such as acetic acid and turpentine which only induce some of the responses (inflammation/hyperplasia) that TPA does but do not act as second-stage promoters (6, 37 Mezerein, 4 ,g, 18 wk 0.1 10 Initiation was with 10 nmol of DMBA; 1 week later, twice-weekly applications of 2 ,ug of TPA were begun. Starting on the third week of promotion, the mice received either twice-weekly applications of various dose levels of mezerein or only acetone. At the end of the experimental period, 295% of the mice were alive. The maximal SD for the groups was 16%. induce inflammation and hyperplasia in mouse skin at the doses used in this experiment. However, at higher doses (100, 250, and 500,ug) it induces a dose-dependent increase in epidermal hyperplasia.
The importance of the number of applications of TPA to cause the first stage of promotion is shown in Table 6 . One application of TPA in a two-stage promotion protocol gave a weak tumor response that was reproducible and significant over the background level. Two and four applications of TPA followed by mezerein showed a good dose-response relationship. With 1 ,gg of TPA given twice weekly for 2 weeks followed by mezerein, again a good dose-response effect was obtained. Mice given 10 nmol of DMBA followed by twice-weekly applications of 2 ,ug of mezerein did not develop tumors after 20 weeks.
In conclusion, tumor promotion can be reproducibly divided into two stages, and mezerein is a potent stage II promoter.
Stage I promotion can be effectively accomplished by limited treatment with TPA which by itself is nonpromoting. In addition, 4-O-methyl-TPA appears to be a weak stage I promoter. It is important to emphasize that, because TPA and mezerein 
